Concepedia

Mark T. Brown

MT

40

Publications

3.4K

Citations

26

H-Index

1971

Active since

Affiliations

Pfizer (United States)(Current)

Duke Medical Center

Eli Lilly (United States)

Northwestern University

Duke University Hospital

Mark T. Brown is an author at Pfizer (United States) specializing in medicine, health sciences, and orthopaedics.

ORCID

Top concepts

Publications per year

1971–2023

40

Publications

40

Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery

Nancy A. Nussmeier, Andrew Whelton, Mark T. Brown et al. · New England Journal of Medicine · 2005 · 1.1K citations · Full text

Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial

Mark T. Brown, Frederick T. Murphy, David Radin et al. · Journal of Pain · 2012 · 194 citations

, , +7

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Darell D. Bigner, Mark T. Brown, Allan H. Friedman et al. · Journal of Clinical Oncology · 1998 · 194 citations

Safety and Efficacy of the Cyclooxygenase-2 Inhibitors Parecoxib and Valdecoxib after Noncardiac Surgery

Nancy A. Nussmeier, Andrew Whelton, Mark T. Brown et al. · Anesthesiology · 2006 · 160 citations · Full text

Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain

Thomas J. Schnitzer, Evan F. Ekman, Egilius L.H. Spierings et al. · Annals of the Rheumatic Diseases · 2014 · 147 citations

Rows per page

1–5 of 40